What is it?
Shield Therapeutics is a pharmaceuticals company that has developed Feraccru, a pill that treats iron deficiency in patients who are intolerant of salt-based iron therapies, and who would otherwise need costly injections at a hospital.
What’s the latest?
Earlier this year the company published data showing Feraccru was as effective as intravenous iron therapies, and it has gained approval to sell the drug in the US.
Its half-year results show sales increased to £2.6million in the six months to June 30, up from £495,000 during the same period last year.
Losses narrowed from £8million to £2.5million as well.
Who backs it?
The company’s main shareholder is venture fund W Health LP, with a 48.1 per cent stake.
Why you should invest
The approval of Feraccru in the US has opened the world’s largest market up to Shield, with an estimated 8million to 9million patients suffering from iron deficiency anaemia.
And why you shouldn’t
The firm is still loss-making and is yet to strike a deal with distribution partners, meaning it cannot complete manufacturing of its product yet.